Skin Pharmacol Physiol:壳聚糖凝胶可有效减少皮肤出油

2022-01-15 MedSci原创 MedSci原创

脂溢性皮肤或油性皮肤一直是影响男性和女性身体和心理的最常见的抱怨之一。壳聚糖是一种生物聚合物,由甲壳素的碱性脱乙酰化获得。(CN)配

脂溢性皮肤或油性皮肤一直是影响男性和女性身体和心理的最常见的抱怨之一。壳聚糖是一种生物聚合物,由甲壳素的碱性脱乙酰化获得。由于其带正电的性质,壳聚糖可以有效地与脂类结合。因此,壳聚糖纳米颗粒(CN)配方可能有利于减少皮肤皮脂。近日,发表于Skin Pharmacol Physiol的一项研究评估了壳聚糖配方在减少皮肤皮脂方面的功效和安全性。

该研究是一项随机、双盲、安慰剂对照试验,纳入24名18-40岁存在临床皮脂溢出的参与者。参与者被随机分配到应用CN和口香糖(CN-G)或安慰剂(仅口香糖),每天两次,持续4周。在基线、第2周和第4周对皮脂水平、角质测量、经表皮失水(TEWL)和临床脂溢性皮炎分级进行了评估。

 

结果显示,在T区,CN-G组的皮脂水平在第4周明显低于安慰剂组(P = 0.043),而对于U区,皮脂水平在组间没有差异。在任何一次访问中,角质测量和TEWL都没有统计学差异。虽然CN-G的临床皮脂溢出分级较低,但与安慰剂相比没有显著差异。少数病例报告了轻度和自限性的脱屑和痤疮状糜烂。

综上所述,该研究结果表明,与安慰剂相比,CN-G凝胶使用4周后在面部T区显示出明显的抗皮脂特性,同时它没有造成明显的皮肤屏障破坏。此外,它可以安全地使用,并具有可接受和最小的副作用。然而,CN对皮脂减少的确切机制还需要进一步调查。

 

原始出处:

 

Chinathip Theerawattanawit, et al., The Efficacy and Safety of Chitosan on Facial Skin Sebum. Skin Pharmacol Physiol. 2022;35(1):23-30. doi: 10.1159/000517965. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908679, encodeId=bb1c19086e981, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 17 20:06:06 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996449, encodeId=2cc919964492f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu May 05 10:06:06 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788457, encodeId=41c41e88457fd, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 12 12:06:06 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787769, encodeId=35c91e877696a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Aug 26 13:06:06 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788958, encodeId=99eb1e8895832, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 07 10:06:06 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461090, encodeId=1c4d1461090ae, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582451, encodeId=2238158245150, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908679, encodeId=bb1c19086e981, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 17 20:06:06 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996449, encodeId=2cc919964492f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu May 05 10:06:06 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788457, encodeId=41c41e88457fd, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 12 12:06:06 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787769, encodeId=35c91e877696a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Aug 26 13:06:06 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788958, encodeId=99eb1e8895832, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 07 10:06:06 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461090, encodeId=1c4d1461090ae, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582451, encodeId=2238158245150, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-05-05 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908679, encodeId=bb1c19086e981, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 17 20:06:06 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996449, encodeId=2cc919964492f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu May 05 10:06:06 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788457, encodeId=41c41e88457fd, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 12 12:06:06 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787769, encodeId=35c91e877696a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Aug 26 13:06:06 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788958, encodeId=99eb1e8895832, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 07 10:06:06 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461090, encodeId=1c4d1461090ae, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582451, encodeId=2238158245150, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908679, encodeId=bb1c19086e981, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 17 20:06:06 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996449, encodeId=2cc919964492f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu May 05 10:06:06 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788457, encodeId=41c41e88457fd, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 12 12:06:06 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787769, encodeId=35c91e877696a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Aug 26 13:06:06 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788958, encodeId=99eb1e8895832, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 07 10:06:06 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461090, encodeId=1c4d1461090ae, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582451, encodeId=2238158245150, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-08-26 jj000001
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908679, encodeId=bb1c19086e981, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 17 20:06:06 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996449, encodeId=2cc919964492f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu May 05 10:06:06 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788457, encodeId=41c41e88457fd, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 12 12:06:06 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787769, encodeId=35c91e877696a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Aug 26 13:06:06 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788958, encodeId=99eb1e8895832, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 07 10:06:06 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461090, encodeId=1c4d1461090ae, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582451, encodeId=2238158245150, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908679, encodeId=bb1c19086e981, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 17 20:06:06 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996449, encodeId=2cc919964492f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu May 05 10:06:06 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788457, encodeId=41c41e88457fd, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 12 12:06:06 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787769, encodeId=35c91e877696a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Aug 26 13:06:06 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788958, encodeId=99eb1e8895832, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 07 10:06:06 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461090, encodeId=1c4d1461090ae, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582451, encodeId=2238158245150, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-01-17 lishizhe
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908679, encodeId=bb1c19086e981, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 17 20:06:06 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996449, encodeId=2cc919964492f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu May 05 10:06:06 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788457, encodeId=41c41e88457fd, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 12 12:06:06 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787769, encodeId=35c91e877696a, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Aug 26 13:06:06 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788958, encodeId=99eb1e8895832, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Jun 07 10:06:06 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461090, encodeId=1c4d1461090ae, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582451, encodeId=2238158245150, content=<a href='/topic/show?id=bda942398cd' target=_blank style='color:#2F92EE;'>#壳聚糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42398, encryptionId=bda942398cd, topicName=壳聚糖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Jan 17 14:06:06 CST 2022, time=2022-01-17, status=1, ipAttribution=)]

相关资讯

一文了解头皮银屑病和脂溢性皮炎的皮肤镜鉴别

银屑病和脂溢性皮炎是相对常见的炎症性皮肤病,具体表现为红斑脱屑。这两种疾病有共同的临床病理特征,但皮肤镜检查时有一些明显的区别。

JEADV:脂溢性皮炎与SARS-CoV-2的相关性研究

脂溢性皮炎(SD)是皮炎的一种常见形式。免疫失调被认为在SD的发病机制中起作用,随着年龄增大、免疫抑制和神经精神疾病的患者,SD的患病率增加。

脸上的红疹子可能是脂溢性皮炎

许多人都经历过脸上出现红色、干燥的皮疹,尤其是鼻子两侧和眉毛区域。该皮疹是由“脂溢性皮炎”引起的,或者称脂溢性湿疹。在大多数人的心目中,脂溢性皮炎指的是头发,也就是头皮屑,或者婴儿的摇篮帽;不过实际上,除了头发,这种皮肤病还会影响脸或其他皮肤区域。1-脂溢性皮炎是什么?脂溢性皮炎是一种炎症性状态。一些细胞的存在,导致皮肤炎症的发生,进而出现皮疹。通常这些皮疹会发红,有时候炎症还会导致头皮发痒。脂溢

2016亚洲脂溢性皮炎治疗共识发布

2016年,来自印度,韩国,台湾,马来西亚,越南,新加坡等亚洲国家的专家在新加坡举行的会议上制订了亚洲溢脂性皮炎治疗共识,以帮助;临床医生在治疗成人和儿童溢脂性皮炎提供推荐意见。该共识包含的内容有,亚洲溢脂性皮炎的流行病学,亚洲和非亚洲皮肤的鉴别,溢脂性皮炎的发病机制,治疗建议等内容。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)